Merck KGaA: First patient has been dosed in the Phase 3 PROCEADE-CRC-03 trial

[출처/시간] Briefing.com - 8:14 AM ET, 05/21/2026

Merck KGaA announces that the first patient has been dosed in the Phase 3 PROCEADE-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem-TcT), a potential first-in-class investigational anti-CEACAM5 antibody-drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). "Leveraging our novel payload-linker technology, Precem-TcT is the first CEACAM5-targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity," said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer, Merck KGaA, Darmstadt, Germany. The PROCEADE-CRC-03 study assesses the efficacy and safety of Precem-TcT, alone or with bevacizumab, in patients with mCRC who are intolerant- or refractory-to, or progressed after, systemic therapies.